ReviewOncogene2001
Transcriptional regulation in acute promyelocytic leukemia.
Review in Oncogene, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed.
- Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer.Frontiers in chemistry · 2022Review
- Omics Technologies to Decipher Regulatory Networks in Granulocytic Cell Differentiation.Biomolecules · 2021Article
- Identification and characterization of a phenyl-thiazolyl-benzoic acid derivative as a novel RAR/RXR agonist.Heliyon · 2019Article
- Review
- Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy.Cancers · 2019Review
- Efficiency of All-Trans Retinoic Acid on Gastric Cancer: A Narrative Literature Review.International journal of molecular sciences · 2018Review
- Profiling and functional analysis of circular RNAs in acute promyelocytic leukemia and their dynamic regulation during all-trans retinoic acid treatment.Cell death & disease · 2018Article
- RaRF confers RA resistance by sequestering RAR to the nucleolus and regulating MCL1 in leukemia cells.Oncogene · 2018Article
- Selenite promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells.Oncotarget · 2016Article
- PU.1 controls the expression of long noncoding RNA HOTAIRM1 during granulocytic differentiation.Journal of hematology & oncology · 2016Article
- The Role of HDACs as Leukemia Therapy Targets using HDI.International journal of hematology-oncology and stem cell research · 2015Article
- Targeting the histone orthography of cancer: drugs for writers, erasers and readers.British journal of pharmacology · 2015Review
- A systems-level interrogation identifies regulators of Drosophila blood cell number and survival.PLoS genetics · 2015Article
- CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells.Journal of hematology & oncology · 2014Article
- Promyelocytic leukemia zinc finger-retinoic acid receptor α (PLZF-RARα), an oncogenic transcriptional repressor of cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) and tumor protein p53 (TP53) genes.The Journal of biological chemistry · 2014Article
- Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation.Oncotarget · 2014Article
- Coordinated regulation of the immunoproteasome subunits by PML/RARα and PU.1 in acute promyelocytic leukemia.Oncogene · 2014Article
- Nuclear receptor corepressor complexes in cancer: mechanism, function and regulation.American journal of clinical and experimental urology · 2014Review
- The DNA binding property of PML/RARA but not the integrity of PML nuclear bodies is indispensable for leukemic transformation.PloS one · 2014Article
- The deubiquitinating enzyme USP37 regulates the oncogenic fusion protein PLZF/RARA stability.Oncogene · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been 10 years since the seminal discovery that a mutant form of a retinoid acid receptor (RARalpha) is associated with acute promyelocytic leukemia (APL). This finding, coupled with the remarkable success of retinoic acid (RA), the natural ligand of RARalpha, in the treatment of APL, has made APL a unique model system in the study of oncogenic conversion of transcription factors in hematological malignancies. Indeed, subsequent basic and clinical studies showed that chromosomal translocation involving the RARalpha gene is the cytogenetic hallmark of APL and that these mutant forms of RARs are the oncogenes in APL that interfere with the proliferation and differentiation pathways controlled by both RAR and their fusion partners. However, it was not until recently that the role of aberrant transcriptional regulation in the pathogenesis of APL was revealed. In this review, we summarize the biochemical and biological mechanisms of transcriptional regulation by mutant RARs and their corresponding wild-type fusion partner PML and PLZF. These studies have been instrumental in our understanding of the process of leukemogenesis in general and have laid the scientific foundation for the novel concept of transcription therapy in the treatment of human cancer.
Indexed as
Identifiers
11704848What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.